ACETO Corp (ACET) Unit Launches Generic Ditropan XL Tablets

November 14, 2016 9:49 AM EST

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

ACETO Corporation (Nasdaq: ACET) announced that Rising Pharmaceuticals, Inc., its finished dosage form generics subsidiary, is launching Oxybutynin Chloride Extended-Release Tablets, USP, an FDA-approved generic version of Janssen Pharmaceuticals, Inc.’s Ditropan XL Tablets.

According to IMS Health data, U.S. market sales for Oxybutynin Chloride Extended-Release Tablets, USP, which is used in the treatment of overactive bladder, were approximately $156 million for the twelve months ended August 31, 2016.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Corporate News

Related Entities

Earnings

Add Your Comment